The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 19 | — | 20.8x | Bottom tier | |
Growth | 80 | 32.8% | 6.1% | Top tier | |
Quality | 47 | -1.2% | 6.6% | Around median | |
Safety | 56 | 24.2x | 0.7x | Around median | |
Capital Return | 12 | — | 2.02% | Bottom tier | |
Momentum | 34 | -40.2% | 4.1% | Bottom tier | |
Sentiment | 76 | 10 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Hims & Hers Health, Inc. (HIMS) is a leading consumer digital healthcare platform, providing users with access to personalized treatments and wellness products in key areas such as hair loss, sexual health, skincare, hormonal health, and weight loss. The company generates its revenue primarily through a recurring online subscription model, allowing patients to have medical consultations with licensed providers and receive personalized prescription medications shipped directly to their homes via a network of affiliated and partner pharmacies.
In the first quarter of 2026, the company generated revenue of $608.1 million, registering a 4% year-over-year growth, and gross profit reached $396.8 million. However, the company recorded a net loss of $92.1 million (EPS of -$0.4) due to exceptional restructuring costs of $33 million, which pressured the GAAP gross margin down to 65% (or 70% on an adjusted basis). The number of subscribers increased by 9% to reach approximately 2.6 million, while international operations achieved massive growth, with revenues reaching $78 million thanks to the acquisition of ZAVA and Livewell.
The analyst consensus rating for Hims & Hers stock currently stands at Hold, with an average price target of $27.00, with estimates ranging from a low of $12.50 to an optimistic high of $60.00. Considering the current market capitalization of $7.0 billion and the wide 52-week historical trading range between $13.74 and $70.43, the stock is affected by margin fluctuations resulting from expansionary investments, but remains supported by robust growth prospects toward the 2030 targets.
Figures in the text are as of 2026-06-17; the live price is shown at the top of the page.
The primary reason for recording a net loss of $92.1 million in the first quarter of 2026 was the company's strategic decision to stop advertising compounded products and focus on branded products. This shift led to non-recurring restructuring costs of $33 million, which included a $28 million asset write-down related to the compounded GLP-1 supply chain that faced obsolescence risk. Despite this temporary paper loss, management expects this step to accelerate subscriber growth and significantly expand the addressable market.
The company's international revenue achieved massive growth in the first quarter of 2026, reaching $78 million thanks to previous acquisitions of ZAVA and Livewell. To bolster this growth, the company plans to complete the acquisition of Eucalyptus in the second half of 2026, where it will pay approximately $240 million at closing with remaining payments extending through early 2029. This transaction will allow the company to expand aggressively into the Australian, Japanese, UK, German, and Canadian markets, leveraging existing local relationships.
The strategic partnership with Novo Nordisk resulted in providing direct access to branded Wegovy products through the Hims & Hers platform, which met with exceptional consumer demand. During just the first six weeks of launching these products, the company fulfilled and shipped more than 125,000 shipments of Wegovy products. This partnership contributes to driving growth in the weight loss segment to record levels, with the company on track to add more than 100,000 new subscribers monthly in this specialty.
Automated analysis for informational purposes only — not investment advice.
The company is highly enthusiastic about the peptides segment and is actively preparing the necessary infrastructure and medical protocols to safely enter this market once regulatory guidance from the FDA becomes clear at the end of July 2026. The company relies on a strong competitive advantage of owning a domestic peptide facility in the US acquired last year, giving it an integrated vertical supply chain to control purity and quality. Management emphasizes that it will not launch these products until meeting the highest safety standards and strict medical oversight to differentiate itself from the unregulated gray market.
The company raised its full-year 2026 revenue guidance to range between $2.8 billion and $3.0 billion, with adjusted EBITDA expected to range between $275 million and $350 million. In the long term, management asserts its full confidence in achieving the 2030 targets of recording revenues of at least $6.5 billion and adjusted earnings of $1.3 billion. The company also expects to return to positive GAAP net profitability by 2027 as operations become more efficient and benefit from economies of scale.